

August 10, 2020

The Manager – Listing  
**BSE Limited,**  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Buiding, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing  
**National Stock Exchange of India Ltd.**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No.C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sir(s),

**Sub: Outcome of the Board Meeting held on Monday, August 10, 2020**

**Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN**


The Board of Directors of the Company at their meeting held today i.e, August 10, 2020, has inter-alia:

1. Approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2020. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 10, 2020 are enclosed herewith.
2. Declared Interim Dividend of Rs. 2/- per equity share for the financial year 2020-21
3. Fixed August 21, 2020 as the Record Date for determining the entitlement of the shareholders for the payment of aforesaid Interim Dividend

• This is for your kind information and records.

Thanking you,

For AstraZeneca Pharma India Limited



**Pratap Rudra**  
Company Secretary & Legal Counsel



AstraZeneca Pharma India Limited  
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045  
Statement of unaudited financial results for the quarter ended 30 June 2020

| Sl No. | Particulars   | Rs in lakhs except for earnings per share data |                                       |   |                          |
|--------|---|--|---------------------------------------|---|--------------------------|
|        |   | 3 months ended<br>30/06/2020                   | Previous 3 months<br>ended 31/03/2020 | Corresponding 3<br>months ended in the<br>previous year<br>30/06/2019 | Year ended<br>31/03/2020 |
|        |   | Unaudited                                      | Refer note 7                          | Unaudited   | Audited                  |
| 1      | Revenue   |  |                                       |   |                          |
|        | a) Revenue from operations  | 19,357.76                                      | 19,490.19                             | 20,456.13   | 83,180.91                |
|        | b) Other income   | 264.80   | 337.64                                | 298.92  | 1,298.79                 |
|        | Total income  | 19,622.56                                      | 19,827.83                             | 20,755.05   | 84,479.70                |
| 2      | Expenses  |  |                                       |   |                          |
|        | (a) Cost of materials consumed  | 2,085.38                                       | 1,652.68                              | 1,875.47  | 7,021.07                 |
|        | (b) Purchase of stock-in-trade  | 4,711.22                                       | 8,721.87                              | 4,667.63  | 27,423.30                |
|        | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 459.18   | (2,402.20)                            | 460.81  | (3,920.84)               |
|        | (d) Employee benefits expense   | 5,634.75                                       | 6,124.82                              | 5,073.41  | 21,670.07                |
|        | (e) Depreciation expense  | 456.16   | 454.45                                | 462.74  | 1,858.36                 |
|        | (f) Allowance for expected credit loss (net)                                      | (17.92)  | 65.70                                 | (37.94)   | 158.27                   |
|        | (g) Selling, marketing and distribution expense                                   | 923.86   | 1,306.43                              | 1,698.33  | 5,575.57                 |
|        | (h) Other expenses  | 2,704.10                                       | 2,540.18                              | 3,162.15  | 13,184.19                |
|        | (i) Finance cost  | 27.39  | 28.64                                 | 29.54   | 113.67                   |
|        | Total expenses  | 16,984.12                                      | 18,492.57                             | 17,392.14   | 73,083.66                |
| 3      | Profit before exceptional and extraordinary items and tax (1-2)                   | 2,638.44                                       | 1,335.26                              | 3,362.91  | 11,396.04                |
| 4      | Exceptional items   | -  | -                                     | -   | -                        |
| 5      | Profit before extraordinary items and tax (3+4)                                   | 2,638.44                                       | 1,335.26                              | 3,362.91  | 11,396.04                |
| 6      | Extraordinary items   | -  | -                                     | -   | -                        |
| 7      | Profit before tax (5+6)   | 2,638.44                                       | 1,335.26                              | 3,362.91  | 11,396.04                |
| 8      | Tax expense (Refer note 5)  |  |                                       |   |                          |
|        | - Current tax   | 859.54   | 485.38                                | 1,269.53  | 3,150.93                 |
|        | - Deferred tax  | (84.57)  | (107.98)                              | (58.16)   | 1,024.02                 |
|        | Total tax expense   | 774.97   | 377.40                                | 1,211.37  | 4,174.95                 |
| 9      | Profit after tax (7-8)  | 1,863.47                                       | 957.86                                | 2,151.54  | 7,221.09                 |
| 10     | Other comprehensive income/(loss)   |  |                                       |   |                          |
|        | A. Items that will not be reclassified to profit or loss                          |  |                                       |   |                          |
|        | Re-measurement gains/(losses) on post employment benefit obligations              | 98.17  | (306.07)                              | (344.04)  | (657.70)                 |
|        | Income tax effect on above  | (24.71)  | 77.03                                 | 120.22  | 165.53                   |
|        |   | 73.46  | (229.04)                              | (223.82)  | (492.17)                 |
|        | Total comprehensive income for the period (9+10)                                  | 1,936.93                                       | 728.82                                | 1,927.72  | 6,728.92                 |
| 11     | Paid-up equity share capital<br>(Face value of Rs 2/- per equity share)           | 500.00   | 500.00                                | 500.00  | 500.00                   |
| 12     | Reserves (excluding revaluation reserves as per balance sheet)                    | -  | -                                     | -   | 35,943.62                |
| 13     | Earnings per equity share of Rs 2/- each (basic and diluted)                      | 7.45   | 3.83                                  | 8.61  | 28.88                    |

PRADIP M KANAKIA Digitally signed by PRADIP M KANAKIA  
Date: 2020.08.10 13:52:11 +05'30'




AstraZeneca Pharma India Limited  
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045  
Statement of unaudited financial results for the quarter ended 30 June 2020

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 3 As previously disclosed, by way of a letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Such proposed delisting was subject to an on-going inquiry with Securities Exchange Board of India (SEBI). During the quarter, SEBI has completed the inquiry and has issued an order dated 5 June 2020. The Company has filed a letter with the NSE and BSE on 8 June 2020 clarifying that the Company is not a noticee in the aforesaid order and being a target company in the delisting process, has no stake in the delisting proposal other than to comply with the mandatory requirements under Delisting Regulations and the procedures prescribed thereunder and the applicable provisions of the Companies Act, 2013.
- 4 **Impact of COVID-19 Pandemic**  
The spread of COVID-19 has severely impacted businesses around the globe. In many countries, including in India, there has been disruption to regular business operations due to lock-downs, disruptions in transportation, supply chain, travel restrictions, quarantines, social distancing and other measures. The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory. Since the products supplied by the Company have been classified as essential goods during the COVID-19 pandemic, Company has been able to continuously supply products to its customers. The Company has also continued to strengthen the measures around safety and well being of its employees, in due compliance with the applicable laws.  
Management has considered its liquidity position as at 30 June 2020 and over the next twelve months from the date of approval of these financial results, by performing cash flow assessments and a sensitivity analysis thereon and has concluded that the Company will have adequate liquidity in the ordinary course of business.  
As at the quarter end, management has assessed the recoverability of the carrying values of property, plant and equipment, trade receivables and inventory and has concluded that no further adjustments are required to be made in respect of such assets as at 30 June 2020.  
As explained above, management has considered all possible impacts of known events arising from COVID-19 pandemic in the preparation of these financial results and therefore, believes that the current pandemic is not likely to have a material impact on the operations and financial position of the Company. However, the impact assessment of COVID-19 is a continuous process given the uncertainties associated with its nature and duration. The Company will continue to closely monitor any material changes to future economic conditions.
- 5 Current tax includes tax provision of Rs. 122.5 lakhs pertaining to a matter of an earlier year.
- 6 The Board of Directors, at its meeting dated 10 August 2020, has declared an interim dividend of Rs. 2/- per equity share aggregating to ~~6~~ Rs 500.0/- lakhs.
- 7 The figures for the quarter ended 31 March 2020 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2020 and the published unaudited year to date figures up to the third quarter of the relevant financial year i.e. 31 December 2019 which were subjected to review by the statutory auditors.
- 8 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 9 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 August 2020. The Statutory Auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2020.

By Order of the Board of Directors  
For AstraZeneca Pharma India Limited

  
Gagandeep Singh Bedi  
Managing Director

Place: Bengaluru  
Date: 10 August, 2020

# Price Waterhouse & Co Chartered Accountants LLP

To  
The Board of Directors  
AstraZeneca Pharma India Limited  
Block N1, 12th Floor,  
Manyata Embassy Business Park,  
Rachenahalli, Outer Ring Road,  
Bengaluru – 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the “Company”) for the quarter ended June 30, 2020 which are included in the accompanying ‘Statement of unaudited financial results for the quarter ended 30 June 2020’ together with the notes thereon (hereinafter referred to as the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

*Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower ‘D’, The Millenia, 1 & 2 Murphy Road  
Ulsoor, Bangalore-560 008  
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222*

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/300009 (ICAI registration number before conversion was 304026E)

# Price Waterhouse & Co Chartered Accountants LLP

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of AstraZeneca Pharma India Limited

Report on the Financial Results

Page 2 of 2

5. We draw attention to Note 4 to the results which explains the uncertainties and management's assessment of the financial impact due to the lock-downs and other restrictions and conditions related to the COVID-19 pandemic situation, for which a definitive assessment of the impact in the subsequent period is dependent upon the circumstances as they evolve. Our opinion is not modified in respect of this matter.

For Price Waterhouse & Co Chartered Accountants LLP  
Firm Registration Number: 304026E/ E-300009

PRADIP M KANAKIA Digitally signed by PRADIP M KANAKIA  
Date: 2020.08.10 13:54:44 +05'30'

Pradip Kanakia  
Partner  
Membership Number: 039985  
UDIN: 20039985AAAACS6689

Place: Bengaluru  
Date: August 10, 2020